# Abbott Laboratories (ABT) FY2025 Annual Balance Sheet

- Company: Abbott Laboratories (ABT)
- Period: As of 2025-12-31
- Filing: FY2025 10-K, filed 2026-02-20, accession number 0001628280-26-010185
- Page: https://plicit.ai/financials/abt/fy2025-annual-balance-sheet
- Chart image: https://plicit.ai/charts/abt-fy2025-annual-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2025-12-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 86,713,000,000 US dollars
- **Current assets**: 25,996,000,000 US dollars
- **Non-current assets**: 60,717,000,000 US dollars
- **Liabilities (calculated)**: 33,942,000,000 US dollars
- **Current liabilities**: 16,496,000,000 US dollars
- **Non-current liabilities**: 17,446,000,000 US dollars
- **Equity**: 52,771,000,000 US dollars
- **Noncontrolling interest**: 641,000,000 US dollars. Included in consolidated equity; this amount is not added again.
- **Land**: 541,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.
- **Buildings**: 4,543,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.
- **Equipment**: 17,571,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.
- **Construction in progress**: 2,567,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.
- **Less: accumulated depreciation and amortization**: negative 13,406,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.
- **Cash and cash equivalents**: 8,522,000,000 US dollars
- **Trade receivables, less allowances of — 2025: $490; 2024: $439**: 7,929,000,000 US dollars
- **Finished products**: 3,976,000,000 US dollars
- **Other prepaid expenses and receivables**: 2,640,000,000 US dollars
- **Materials**: 1,608,000,000 US dollars
- **Work in process**: 904,000,000 US dollars
- **Investments, primarily bank time deposits and U.S. treasury bills**: 417,000,000 US dollars
- **Goodwill**: 24,035,000,000 US dollars
- **Deferred income taxes and other assets**: 18,422,000,000 US dollars
- **Net property and equipment**: 11,816,000,000 US dollars
- **Intangible assets, net of amortization**: 5,526,000,000 US dollars
- **Investments**: 918,000,000 US dollars
- **Other accrued liabilities**: 5,812,000,000 US dollars
- **Trade accounts payable**: 4,240,000,000 US dollars
- **Current portion of long-term debt**: 3,033,000,000 US dollars
- **Salaries, wages, and commissions**: 1,745,000,000 US dollars
- **Dividends payable**: 1,097,000,000 US dollars
- **Income taxes payable**: 569,000,000 US dollars
- **Long-term debt**: 9,896,000,000 US dollars
- **Post-employment obligations and other long-term liabilities**: 7,550,000,000 US dollars
- **Earnings employed in the business**: 49,781,000,000 US dollars
- **Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2025: 1,996,795,525; 2024: 1,991,472,630**: 25,527,000,000 US dollars
- **Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued**: 0 US dollars
- **Noncontrolling interests in subsidiaries**: 641,000,000 US dollars
- **Common shares held in treasury, at cost — Shares: 2025: 260,196,074; 2024: 259,774,639**: negative 17,177,000,000 US dollars
- **Accumulated other comprehensive income (loss)**: negative 6,001,000,000 US dollars
- **Gross equity (calculated)**: 75,949,000,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.